NCT07724535 18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
| NCT ID | NCT07724535 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Peking University Cancer Hospital & Institute |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-06-24 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2026-06-24 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.
Eligibility Criteria
Inclusion Criteria: 1. 18-75 years old; 2. ECOG score 0 or 1 point; 3. Participants with suspected or confirmed non-small cell lung cancer or melanoma who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging. Exclusion Criteria: 1. Pregnant or nursing; 2. Severe hepatic or renal dysfunction; 3. Low WBC (less than 3 x 10\^9/L); 4. Unable to comply with the PET/CT imaging procedures.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07724535 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07724535 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07724535 currently recruiting?
Yes, NCT07724535 is actively recruiting participants. Contact the research team at zhanglinyu1@pku.edu.cn for enrollment information.
Where is the NCT07724535 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07724535 clinical trial?
NCT07724535 is sponsored by Peking University Cancer Hospital & Institute. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.